TOPICAL USE OF MICRONIZED PROGESTERONE IN REPRODUCTIVE-AGE PATIENTS WITH MASTOPATHY


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. To study of the effect of micronized progesterone on the clinical manifestations of mastopathy, the biometric characteristics of the parenchyma, and the rate of breast circulation. Subjects and methods. Micronized progesterone as skin applications was used to treat mastopathy in 42 patients. For the objective characterization of the intensity of pain syndrome, the authors employed the incidence of mastopathy, its mean duration, the nature of pain (distending, aching pain, a sensation of heaviness, exercise-induced pain syndrome; the intensity of mastalgia according to the visual analog scale: mild with a 1-to-3-cm section; moderate, from 4 to 7 cm; severe, from 7 cm or more). Follow-up monitoring of the clin ical picture of the disease, Doppler ultrasound parameters of resistance to blood flow in the breast parenchymal arteries was made before and 3 and 6 months after the initiation of therapy. Results. With the use of micronized progesterone, the rate of mastalgia decreased 2.5- and 3-fold (from 100 to 36% and from 36 to 12%) following 3 and 6 months, respectively. After 6 months of therapy, the thickness of the glandular layer was reduced to 10.78±0.47 mm, which was 1.3 mm time less than that after 3-month therapy (p<0.05). Following 3-month therapy, there were increases in the pulsatility index (PI) by 1.8 times (from 0. 80 to 1. 44%; p<0.001) and resistivity index (RI) by 1.6 times (from 0.46 to 0.76; p<0.001). Following 6 months, there were significant 2-fold increases in PI (from 0.80 to 1.64; p<0.001) and RI (from 0.46 to 0.90; p<0.001), and a 1.5-fold rise in the systolic/diastolic ratio (from 2.89 to 4.39; p<0.05). Conclusion. The use of micronizedprogesterone in patients with mastopathy causes reductions in the duration, intensity, and nature of mastalgia, a change in biometric (decreases in the thickness of the parenchyma, the number of cysts, and the diameter of lactiferous ducts) and functional (hemodynamic) characteristics of the breast.

Texto integral

Acesso é fechado

Sobre autores

I. KOGAN

D.O. Ott Research Institute of Obstetrics and Gynecology, North-Western Branch, Russian Academy of Medical Sciences

Email: iagmail@ott.ru
Saint Petersburg

E. MUSINA

D.O. Ott Research Institute of Obstetrics and Gynecology, North-Western Branch, Russian Academy of Medical Sciences

Saint Petersburg

Bibliografia

  1. Ботвич Т.А., Кожевникова Т.А., Недобыльская Ю.П. Влияние прогестерона на активность магниевой атф-азы микрососудов яичников и матки // Естествознание и гуманизм. — 2007. — Т. 4, № 4. — С.29.
  2. Коган И.Ю. Гиперпластические процессы в молочных железах у женщин (патогенез, прогнозирование течения): Автореф. дис..д-ра мед. наук. — СПб., 2008.
  3. Мусина Е.В. Механизмы влияния и эффективность препаратов прогестерона при фиброзно-кистозной болезни молочных желез в репродуктивном возрасте: Автореф. дис.. канд. мед. наук. - СПб., 2011.
  4. Семиглазов В.Ф., Веснин А.Г., Моисеенко В.М. Минимальный рак молочной железы (профилактика, выявление, лечение). — СПб.: Гиппократ, 1992.
  5. Сидоренко Л.Н. Мастопатия: психосоматические аспекты. — 2-е изд. — Л.: Медицина, 1991.
  6. Чумаченко П.А., Панкратова Е.С. Дисгормональная патология молочных желез у женщин зрелого и пожилого возраста // Материалы межрегиональной научно-практической конференции. — Рязань, 1996.— С. 153—155.
  7. Чумаченко П.А., Хмельницкий О.К., Шлыков И.П. Молочная железа и эндокринный гомеостаз. — Воронеж: ВГУ, 1987.
  8. Clarke C.L., Sutherland R.L. Progestin regulation of cellular proliferation // Endocr.Rev. — 1990. — Vol. 11, № 2. — P. 266—301.
  9. Druckmann R. Progestins and their effects on the breast // Maturitas. — 2003. — Vol. 46 (suppl. 1). — P. 59-69.
  10. Foidart J.M. et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells // Fertil. And Steril. — 1998. — Vol. 69. — P. 963-969.
  11. Iruela-Arispe M.L. et al. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progestins, in the human endometrium // J. Clin. Invest. — 1996. — Vol. 97. — P. 403—412.
  12. Lange C.A., Richer J.K., Horwitz K.B. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals // Mol. Endocrinol. — 1999. — Vol. 13, № 6. — P. 829-836.
  13. Miller V.M., Vanhoutte P.M. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries // Am. J. Physiol. — 1991. — Vol. 261. — Р. 1022—1027.
  14. Orshal J.M., Khalil R.A. Gender, sex hormones, and vascular tone // Am. J. Physiol. Regul. Integr. Comp. Physiol. — 2004. — Vol. 286. — P. 233—246.
  15. Pasqualini J.R. Differential effects of progestins on breast tissue enzymes // Maturitas. — 2003. — Vol. 46 (Suppl. 1). — P. 45-54.
  16. Pike M.С. et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk // Epidemiol. Rev. — 1993. — Vol. 15, № 1. — P. 17-35.
  17. Schindler A.E., Schindler E.M. Mechanism of action of danazol, personal clinical experiences and guidelines for the treatment of benign breast diseases // Gynäkologe. — 1989. — Vol. 22, № 4 — Р. 271—273.
  18. White M. et al. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms // Endocr. Rev. — 1995. — Vol. 16. — P. 739-751.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2012

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies